OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Hematology is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
	616
Therapeutic Errors Associated With Antithrombotic Medications Reported to United States Poison Centers	351
Clonal Hematopoiesis and Thrombosis	253
The latest insights into rare blood disorders: Diagnosis and treatment strategies	194
Cytopenias revealing a case of carcinocythemia with bone marrow metastasis	185
Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon	150
Overall Survival in Male Patients With Advanced Hematological Disease (Mostly Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in Allogeneic Stem Cell Transpl	138
Primary Effusion Lymphoma Prognostic Score (PEL‐PS): A Validated International Prognostic Score in HIV‐Associated Primary Effusion Lymphoma	136
Hemolysis after high‐dose intravenous immunoglobulin: An under‐appreciated sequelae	110
Not All Tryptase Elevations Are due to Acquired Clonal Mast Cell Disorders: When Tryptase Gene Copy Number Analysis Becomes Critical	92
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations	91
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia	90
The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases	84
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative	84
A First‐In‐Human Phase 1 Study of a Novel BCMA × CD3 Bispecific T Cell Engager	81
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms	80
Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies	78
Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia	78
Acute thrombocytopenia suggesting thrombotic microangiopathy	78
Characteristics and prevalence of antibiotic allergies in patients with sickle cell disease: A single‐center retrospective study	78
A t(6;14;9)(p22;q22;q34) three‐way translocation: Description of a cytogenetically visible variant t(6;9) in acute myeloid leukemia	76
Introduction to American Journal of Hematology Supplement: Improving Initial Care for Acute GVHD Patients	75
Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis	67
Aspirin use in essential thrombocythemia: Once‐daily or twice‐daily or not at all?	66
Are veterans at increased risk of myeloproliferative neoplasms?	65

Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis	64
Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome	64
TEG and ROTEM : Technology and Clinical Applications, 2026 Update	64
History of Thrombosis at High Altitude Associates With Increased Erythropoietin	62
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia	61
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers	61
Teclistamab in patients with multiple myeloma and impaired renal function	60
The insertion site is the main risk factor for central venous catheter‐related complications in patients with hematologic malignancies	60
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML	58
Dendritic cell vaccines extend CAR T‐cell persistence and improve the efficacy of CD19 CAR T‐cell therapy in refractory or relapsed adult B‐ALL patients	57
Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data	56
Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity	56
R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study	54
The impact of sex on platelet responses to aspirin in patients with peripheral artery disease	54
Molecular and clinicopathologic characterization of pediatric histiocytoses	53
Table of Contents	53
Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis and Splanchnic Vein Thrombosis: A Case Series	52
Critical Blue‐Green Neutrophilic Inclusions in the Context of CD19 CAR‐T Toxicity	52
Acute myeloid leukemia with mutated TP53: Is this newly proposed entity oversimplifying a complex group of neoplasms?	51
Persistent Sweet syndrome post‐hematopoietic stem cell transplantation heralding molecular relapse of myelofibrosis	49